News

IMI launches €196m project
Enlarge image

FundingBelgiumEUGermany

IMI launches €196m project

08.02.2013 - The EU’s IMI has launched a novel platform for drug screening. It is aimed at screening 500,000 compounds to find new lead structures.

Under the umbrella of the European Lead Factory, an international consortium of 30 partners led by German Bayer Pharma AG and Taros Chemicals GmbH & Co KG will screen 300,000 compounds provided by seven pharma companies: Bayer, AstraZeneca AB, H. Lundbeck A/S, and Janssen Pharmaceutica NV, Merck KGaA, Sanofi, and UCB Pharma SA. Additionally, the academic and SMEs will synthesise a library of 200,000 completely novel compounds. The pharma companies will screen this new chemical space.

Additionally, the academic and SME partners will screen the compound library with their own assays generating new IP within a newly established European Screening Centre. The EU will fund the project with €80m. The Joint European Compound Collection will be accessible to all project partners and to public organisations offering promising new targets for drug discovery screening.

„The seven EFPIA partners will, for the first time, open their compound libraries for public researchers“, Taros’ CEO Dr Dimitrios Tzalis told EuroBiotechNews. „This open access approach is a novelty and may lead to significant progress in the field of drug development.“ Hanno Wild, Senior VP and Head of Candidate Generation & Exploration at Project Coordinator Bayer HealthCare Global Drug Discovery, says: ‘The European Lead Factory is an outstanding example of a project in which public-private partnerships enable collaborative drug discovery.“ The Innovative Medicines Initiave is a industry-driven Public Private Partnership between the European Commission and the EU pharma association EFPIA that aims to boost productivity of drug development.

© eurobiotechnews.eu/tg 

http://www.european-biotechnology-news.com/news/news/2013-01/imi-launches-eur196m-project.html

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

RegulationItalyGermanyNetherlandsEU

28.11.2014 The first gene therapy for a rare genetic condition — UniQure's Glybera — is on its way to the European market. But there is a hefty price tag: Chiesi, responsible for the marketing of the orphan drug, is asking for a record price of €1.1m per patient.

Events

All Events

Current issue

All issues

Product of the week

Products